Safety of flurbiprofen in subjects with G-6-PD deficiency. In vivo and in vitro results.
The safety of flurbiprofen, a new non-steroidal anti-inflammatory drug was tested in individuals with G-6-PD deficiency. The study was carried out in vitro evaluating the erythrocyte levels of reduced glutathione under basal conditions and after incubation with the drug or acetylphenyl-hydrazine. In the red cells marked with 51Cr, survival was evaluated in vivo before and during flurbiprofen administration. The study shows that flurbiprofen has no oxidating activity in carriers of the G-6-PD Mediterranean variant.
D000293:Adolescent; D000328:Adult; D004905:Erythrocyte Aging / Q000187:drug effects; D005480:Flurbiprofen / Q000009:adverse effects*; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood*; D005978:Glutathione / Q000097:blood; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000009:adverse effects*
D011422:Propionates; D005480:Flurbiprofen; D005978:Glutathione